Blog

October 2 2018 Issue

1. Featured Article: Nusinersen in spinal muscular atrophy type 1 patients older than 7 months: a cohort study

2. What’s Trending: MRI-guided thrombolysis for stroke with unkown time of onset (WAKE-UP study)

In the first segment, Dr. Ted Burns talks with Dr. Laurent Servais about his paper on safety and efficacy of nusinersen treatment in patients with SMA type 1 older than 7 months. In the second part of the podcast, we are featuring a discussion with Dr. Jim Siegler and Dr. Christian Gerloff on the results of the WAKE-UP stroke trial.

DISCLOSURES: Dr. Servais has served as scientific consultant in the S.A.B of Roche, Biomarin, aTyr Pharma, Dynacure, Biogen, Bamboo, Sarepta, and Avexis; has received speaker honoraria gave lecture sponsored by Biomarin, Biogen, and Sarepta; holds patents as co-inventor of the Moviplate device, and of Actimyo; has consulted for Bamboo therapeutics, Pfizzer, Anagenesis, Avexis, and Dynacure; has received research support from NHS, Valerion, Dynacure, Avexis, Biogen, Roche, FP7 programs Skip and Scope, Université de Liège, and Association Française contre les Myopathies.
October 2 2018 Issue
Source: New feed